Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic gene therapy for arthritis.

Y Chernajovsky1

  • 1Molecular Biology Laboratory, Kennedy Institute of Rheumatology, London, UK.

Drugs of Today (Barcelona, Spain : 1998)
|September 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assembly PCR synthesis of optimally designed, compact, multi-responsive promoters suited to gene therapy application.

Scientific reports·2016
Same author

Differences between disease-associated endoplasmic reticulum aminopeptidase 1 (ERAP1) isoforms in cellular expression, interactions with tumour necrosis factor receptor 1 (TNF-R1) and regulation by cytokines.

Clinical and experimental immunology·2014
Same author

Historical development of monoclonal antibody therapeutics.

Handbook of experimental pharmacology·2007
Same author

Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis.

The journal of gene medicine·2007
Same author

Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent.

Annals of the rheumatic diseases·2007
Same author

The differential expression of corticosteroid receptor isoforms in corticosteroid-resistant and -sensitive patients with rheumatoid arthritis.

Rheumatology (Oxford, England)·2006
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Gene therapy using cytokines and inhibitors shows promise for treating collagen-induced arthritis in mice. These approaches target immune functions and offer potential for human therapies.

Area of Science:

  • Immunology
  • Gene Therapy
  • Autoimmune Diseases

Background:

  • Antibodies to tumor necrosis factor (TNF)-alpha and inhibitory cytokines demonstrate therapeutic benefits.
  • Gene delivery of these molecules has shown efficacy in preclinical models of autoimmune arthritis.

Purpose of the Study:

  • To evaluate the therapeutic potential of gene delivery for autoimmune arthritis.
  • To investigate the effects of various gene therapy agents on immune functions in a mouse model.

Main Methods:

  • Testing transforming growth factor (TGF)-beta 1 and interferon (IFN)-beta gene delivery.
  • Utilizing TNF receptors and complement inhibition strategies.
  • Engineering chimeric antibodies for T-cell targeting to collagen type II.

Related Experiment Videos

Main Results:

  • Gene delivery of cytokines and inhibitors proved therapeutically beneficial in the collagen-induced arthritis model.
  • Observed clinical benefits correlated with modulation of immune functions.
  • Inhibition of the complement system affected B- and T-cell functions.

Conclusions:

  • Gene therapy approaches, including cytokine and inhibitor delivery, are effective in a mouse model of autoimmune arthritis.
  • Targeting T-cells to specific antigens like collagen type II is a viable strategy.
  • These preclinical findings suggest potential for human translation in autoimmune diseases.